Cargando…

Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma

Lung adenocarcinoma patients with epidermal growth factor receptor (EGFR)-activating mutations respond well to tyrosine kinase inhibitors but typically develop resistance. Current therapies mainly target differentiated cells, not cancer stem cells (CSCs), but CSCs affect the occurrence, invasion, me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Hong, Liu, Yiwen, Kong, Jinyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383010/ https://www.ncbi.nlm.nih.gov/pubmed/34425505 http://dx.doi.org/10.1016/j.tranon.2021.101204

Ejemplares similares

Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells
por: Ni, Jie, et al.
Publicado: (2018)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Lentivirus‐mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro
por: Li, Ya‐Qing, et al.
Publicado: (2017)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
por: He, Jian, et al.
Publicado: (2023)

Identification of Key Genes and Pathways in Gefitinib-Resistant Lung Adenocarcinoma using Bioinformatics Analysis
por: Mao, Kailin, et al.
Publicado: (2021)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
por: Yang, Chih-Jen, et al.
Publicado: (2017)

FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer
por: Sun, Cuilan, et al.
Publicado: (2020)

Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib
por: Kim, Hyojeong, et al.
Publicado: (2013)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line
por: JIANG, HAO, et al.
Publicado: (2014)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
por: Zhao, Liang, et al.
Publicado: (2015)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
por: Liu, Yu-Tao, et al.
Publicado: (2015)

Cross-Resistance of Acquired Radioresistant Colorectal Cancer Cell Line to gefitinib and regorafenib
por: Afshar, Saeid, et al.
Publicado: (2020)

miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
por: Ge, Peng, et al.
Publicado: (2019)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Comprehensive Analysis of Circular RNA Expression Profiles in Gefitinib-Resistant Lung Adenocarcinoma Patients
por: Zou, Junyong, et al.
Publicado: (2022)

Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma
por: Liu, Chien-Ming, et al.
Publicado: (2015)

Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance
por: Lian, Zeng-Zhi, et al.
Publicado: (2016)

Influence of Autophagy Inhibition on Lung Adenocarcinoma Cell Migration and Invasion Ability, and Efficacy of Gefitinib
por: Liu, Ying, et al.
Publicado: (2021)

Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma
por: WANG, ZHUN, et al.
Publicado: (2015)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Screening Circular RNAs Related to Acquired Gefitinib Resistance in Non-small Cell Lung Cancer Cell Lines
por: Wen, Chunjie, et al.
Publicado: (2020)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

FGFR1 Induces Acquired Resistance Against Gefitinib By Activating AKT/mTOR Pathway In NSCLC
por: Zhang, Dan, et al.
Publicado: (2019)

FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop
por: Wang, Yu, et al.
Publicado: (2016)

Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
por: Choi, Hayoung, et al.
Publicado: (2015)

Mechanism research of miR‐34a regulates Axl in non‐small‐cell lung cancer with gefitinib‐acquired resistance
por: Xiong, Ran, et al.
Publicado: (2019)

Identification of Hub Genes and Small Molecule Drugs Associated with Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer
por: Li, Guangda, et al.
Publicado: (2021)

Identification of Gefitinib Resistance-Related lncRNA-miRNA-mRNA Regulatory Networks and Corresponding Prognostic Signature in Patients with Lung Adenocarcinoma
por: Wang, Taoli, et al.
Publicado: (2022)

Hinokitiol Induces DNA Damage and Autophagy followed by Cell Cycle Arrest and Senescence in Gefitinib-Resistant Lung Adenocarcinoma Cells
por: Li, Lan-Hui, et al.
Publicado: (2014)

Acute effect of combined exercise with aerobic and resistance exercises on executive function
por: Chen, Ying-Chu, et al.
Publicado: (2023)

Clinical Implications of the Autophagy Core Gene Variations in Advanced Lung Adenocarcinoma Treated with Gefitinib
por: Yuan, Jupeng, et al.
Publicado: (2017)

Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib
por: Gozzi, Fabrizio, et al.
Publicado: (2021)

Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma
por: Lee, Joo Young, et al.
Publicado: (2012)

Anti-Proliferative Effect of Cytohesin Inhibition in Gefitinib-Resistant Lung Cancer Cells
por: Bill, Anke, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_l640j1re58o56grjq0ivdnh0d5